First‐ and second‐degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and white women

Traci N. Bethea & Lauren C. Peres et al. · 2021-02-17

Abstract

Family history (FH) of ovarian cancer and breast cancer are well‐established risk factors for ovarian cancer, but few studies have examined this association in African American (AA) and white women by histotype. We assessed first‐ and second‐degree FH of ovarian and breast cancer and risk of epithelial ovarian cancer in the Ovarian Cancer in Women of African Ancestry Consortium. Analyses included 1052 AA cases, 2328 AA controls, 2380 white cases and 3982 white controls. Race‐specific odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multilevel logistic regression with adjustment for covariates. Analyses were stratified by histotype (high‐grade serous vs others). First‐degree FH of ovarian cancer was associated with high‐grade serous carcinoma in AA (OR = 2.32, 95% CI: 1.50, 3.59) and white women (OR = 2.48, 95% CI: 1.82, 3.38). First‐degree FH of breast cancer increased risk irrespective of histotype in AAs, but with high‐grade serous carcinoma only in white women. Associations with second‐degree FH of ovarian cancer were observed for overall ovarian cancer in white women and with high‐grade serous carcinoma in both groups. First‐degree FH of ovarian cancer and of breast cancer, and second‐degree FH of ovarian cancer is strongly associated with high‐grade serous ovarian carcinoma in AA and white women. The association of FH of breast cancer with high‐grade serous ovarian carcinoma is similar in white women and AA women, but may differ for other histotypes.

Funding
An assessment of whether aspirin and/or vitamin D improves breast cancer outcomes in Black women and the modifying effect of genetic variantsBio Repository CoreCollaborative Genetic Study of Ovarian Cancer RiskSouthern Community Cohort StudyA Follow-up Study for Causes of Illness in Black WomenCancer Research Training and Education CoordinationNHLBI NIH HHS Grant HHSN268201600004CThe Molecular Epidemiology Of Ovarian CancerSouthern Community Cohort StudyWomen's Health Initiative Cancer Survivor CohortNHLBI NIH HHS Grant HHSN268201600002CA Follow-up Study for Causes of Cancer in Black WomenNHLBI NIH HHS Grant HHSN268201600018CA Follow-up Study for Causes of Cancer in Black WomenNHLBI NIH HHS Grant HHSN268201600003CCancer Center Support GrantNHLBI NIH HHS Grant HHSN268201600001CExploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortiumLife and Longevity After Cancer (LILAC): The Women's Health Initiative Cancer Survivor CohortHormone Therapy and Risk of Ovarian CancerEpidemiology of Ovarian Cancer in African-American WomenNational Heart, Lung, and Blood Institute Grant NIH/NHLBI‐CSB‐WH‐2016‐01‐CMNational Heart, Lung, and Blood Institute Grant UM1‐CA173642‐05National Heart, Lung, and Blood Grant HHSN268201600004CNational Heart, Lung, and Blood Grant HHSN268201600003CNational Heart, Lung, and Blood Grant HHSN268201600002CNational Heart, Lung, and Blood Grant HHSN268201600001CNational Heart, Lung, and Blood Grant HHSN268201600018CThe National Cancer Institute Grant U01‐CA202979The National Cancer Institute Grant P30‐CA014089The National Cancer Institute Grant P30‐CA68485The National Cancer Institute Grant R01‐CA092447The National Cancer Institute Grant R01‐CA076016The National Cancer Institute Grant R01‐CA58598The National Cancer Institute Grant R01‐CA17054National Cancer Institute Grant R01‐CA142081The National Cancer Institute Grant R01‐CA61093The National Cancer Institute Grant U01‐CA164974The National Cancer Institute Grant UM1‐CA164974The National Cancer Institute Grant R01‐CA058420The National Cancer Institute Grant K01‐CA212056The National Cancer Institute Grant R01‐CA207260

NCI NIH HHS

K01 CA212056

NIMHD NIH HHS

U54 MD010722

NCI NIH HHS

R01 CA058598

NCI NIH HHS

R01 CA092447

NCI NIH HHS

R01 CA058420

NCI NIH HHS

P30 CA014089

NCI NIH HHS

R01 CA076016

NCI NIH HHS

U01 CA202979

NCI NIH HHS

UM1 CA173642

NCI NIH HHS

U01 CA164974

NCI NIH HHS

UM1 CA164974

NCI NIH HHS

P30 CA068485

NCI NIH HHS

R01 CA207260

NCI NIH HHS

U01 CA173642

NCI NIH HHS

P01 CA017054

NCI NIH HHS

R01 CA142081